Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Adipotide (FTPP) peptide icon, one bubble per amino acidAdipotide (FTPP)9 residuesCKGGRAKDCEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Adipotide (FTPP)

Beginner tier: 0.5 mg, daily · preclinical extrapolation

Weight LossResearch
~2-4 hours half-life (estimated)·Injection

Also known as: FTPP, Fat-Targeted Proapoptotic Peptide, Prohibitin-TP01

Obese rhesus monkeys lost 38% of their total body fat in 28 days. Adipotide (FTPP, Prohibitin-TP01) is a chimeric peptidomimetic that starves fat cells by destroying the blood vessels feeding them. The mechanism worked so well it couldn't be separated from kidney damage. MD Anderson's Phase 1 human trial was terminated for nephrotoxicity at doses 70 times below the effective primate dose. Arrowhead Research shut down all clinical development in 2019. A small number of forum users still attempt very low doses with kidney monitoring, but the community consensus calls this "impressive science, too dangerous to use."

What Is Adipotide (FTPP)?

Obese monkeys lost 7 to 15% of their body weight in four weeks. That's the headline from Barnhart and colleagues' 2011 primate study [1], published in Science Translational Medicine. MRI and DEXA confirmed a 38% drop in total body fat and 27% reduction in abdominal fat. Insulin resistance improved alongside the fat loss.

Adipotide (also called FTPP or Prohibitin-TP01) is a synthetic peptidomimetic with two connected domains. The homing peptide (CKGGRAKDC) locks onto prohibitin on the surface of blood vessel cells lining white adipose tissue. The proapoptotic domain, D(KLAKLAK)2, then destroys those endothelial cells from the inside by collapsing their mitochondrial membranes. Without blood supply, downstream fat cells die from oxygen starvation.

The mechanism is genuinely different from anything else in weight loss pharmacology. GLP-1 agonists suppress appetite. Adipotide physically dismantles the vasculature feeding fat depots.

Then the kidneys became the problem. Every treated primate showed dose-dependent renal lesions. When MD Anderson ran a Phase 1 human trial in 2012, nephrotoxicity appeared at 0.03 mg/kg/day, roughly 70-fold lower than the primate effective dose. The trial was terminated. All clinical development ended permanently in 2019; no new trials are registered or planned. Adipotide sits in an almost unique pharmacological category: dramatic efficacy that cannot be separated from its own toxicity. It's available only as a research chemical with no pharmaceutical-grade product on the market.

How Adipotide (FTPP) Works

Two functional domains joined by a glycine-glycine linker. That's the architecture of adipotide.

The N-terminal homing domain (CKGGRAKDC) is a cyclic peptide identified through in vivo phage display screening. It binds prohibitin (PHB), a membrane protein on the luminal surface of endothelial cells lining white adipose tissue vasculature. Prohibitin sits in a trimolecular complex with annexin A2 and CD36, regulating fatty acid transport from blood into fat tissue.

Once prohibitin binding occurs, the peptide enters the cell through receptor-mediated endocytosis. The C-terminal proapoptotic domain takes over from there. D(KLAKLAK)2 is a synthetic amphipathic peptide built entirely from D-amino acids, making it resistant to proteolytic degradation. Inside the cell, this domain localizes to the mitochondrial outer membrane. Its amphipathic structure inserts into that membrane and disrupts it. Membrane potential collapses. Cytochrome c releases. Caspases activate. The intrinsic apoptotic cascade kills the endothelial cell.

Scale that process across the microvasculature of a fat depot and you get ischemic death of the adipocytes downstream. No blood supply means no oxygen, no nutrients, no survival.

The kidney problem traces to the same domain. During renal filtration and excretion, D(KLAKLAK)2 causes collateral apoptosis in proximal tubular epithelial cells. The compound can't distinguish between target endothelial cells and kidney cells it passes through during clearance.

Adipotide (FTPP) Benefits

  • Adipotide benefits center on a fat-reduction mechanism that exists nowhere else in weight loss pharmacology.
  • 7 to 15% total body weight lost in 28 days in obese rhesus monkeys (Barnhart et al., Science Translational Medicine)[1].
  • 38% reduction in total body fat and 27% reduction in abdominal fat, confirmed by MRI and DEXA in the same primate study.
  • Insulin resistance improved alongside fat loss in primate models, suggesting metabolic benefits beyond simple weight reduction.
  • Targets white adipose tissue vasculature through prohibitin binding with high selectivity; the homing peptide was identified through in vivo phage display from billions of candidates.
  • Fat loss occurs without appetite suppression. Unlike GLP-1 agonists, the mechanism doesn't touch hunger signaling. Community users who tried low doses report eating normally while fat composition changed.
  • Rapid onset compared to other weight management approaches. Primate data showed detectable body composition changes within two weeks of treatment.

Adipotide (FTPP): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 8 key studies·Research only

Adipotide produced dramatic fat loss in primate studies: 7–15% body weight, 38% total fat in 28 days.

Dosing studied: Primate effective: 0.43 mg/kg/day. Human trial start: 0.03 mg/kg/day (~2.1 mg for 70 kg). No safe effective human dose identified.
Read the evidence (key study, limitations)

The mechanism (vascular ablation of adipose tissue) is well-characterized and genuinely novel. However, dose-dependent nephrotoxicity was observed in every treated animal, and the Phase 1 human trial was terminated due to kidney toxicity at doses 70x below the effective primate dose. No human efficacy data exists. All clinical development was discontinued in 2019. No new clinical trials are registered or planned as of 2026.

Key Study

Barnhart et al. 2011, "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys" (Sci Transl Med, PMID 22072637)

Limitations

No completed human trial. Primate efficacy cannot be separated from primate nephrotoxicity: the effective dose range overlaps the toxic dose range. Human kidneys appear far more sensitive than primate kidneys.

Community Experience
Weak
2.5/5
Based on ~100–200 threads estimated across all forums

Community interest is infamy-driven: most threads discuss the danger rather than personal use.

Community dosing: 0.5–1.0 mg/day for 14–28 days (the few who report trying it)
Read the reports (what users report 3, common issues 5)

A small number of users on MESO-Rx, ExcelMale, and other forums report trying 0.5–1 mg/day for short runs. Reports of fat loss exist but are sparse, uncontrolled, and overshadowed by the Bostin Loyd death. The overwhelming consensus is "impressive science, too dangerous to use."

What users report (3)
  • Some users report noticeable fat loss within 2 weeks at 0.5–1 mg/day
  • Mechanism targets stubborn fat deposits specifically
  • Fat loss without appetite changes (distinct from GLP-1 experience)
Common issues (5)
  • Kidney function changes observed even at low community doses
  • No way to know if you're in the "sensitive" population until damage occurs
  • Community-documented death (Bostin Loyd at ~5 mg/day)
  • Extremely limited user pool: hard to draw conclusions from so few reports
  • Source quality concerns: no pharmaceutical-grade product exists
Partially Aligned

Science and community agree that adipotide causes fat loss and damages kidneys. They diverge on whether any dose is usable: science says no (the trial was terminated), while a tiny minority of community users attempt very low doses with monitoring. The community is not enthusiastic: this is not a BPC-157 or semaglutide situation. Most forum discussions are cautionary, not protocol-sharing.

Adipotide (FTPP) Dosage Guide

ExtrapolatedDose extrapolated from primate study (PMID 21734721) using allometric scalingSource (opens in a new tab)
LevelDose / InjectionFrequency
Beginner0.5 mg
DailyTrack
Moderate1 mg
DailyTrack
Aggressive2 mg
DailyTrack
Note:

Start with the math. A 5 mg vial reconstituted with 2 mL bacteriostatic water gives you 2.5 mg/mL. At 0.5 mg per dose, that's 0.2 mL per injection, or 20 units on an insulin syringe. One 5 mg vial covers 10 days at that dose. A full 28-day cycle at 0.5 mg/day needs roughly three 5 mg vials (14 mg total).

Store lyophilized powder at -20C. This compound degrades faster than simpler peptides at warmer temperatures. Once reconstituted, refrigerate at 2 to 8C and use within 14 days.

The thing most people miss: the effective primate dose (0.43 mg/kg/day) translates to about 30 mg/day for a 70 kg human. Community doses of 0.5 to 1 mg/day are 30 to 60 times lower. You're almost certainly below the therapeutic threshold, and that's intentional. You'll hit kidney toxicity before you hit efficacy if you try to close that gap.

Get a full renal panel before you start. Creatinine, BUN, urinalysis, GFR. Repeat at day 7 and day 14. If creatinine moves more than 20% from baseline, you're done. Stop NSAIDs at least a week before starting. Drink 3-plus liters of water daily; your kidneys concentrate this peptide during excretion.

Cycling Protocol

On Period
4 weeks
Off Period
8 weeks

All published research used 28-day (4-week) treatment cycles. Extended use beyond 28 days has not been studied and is strongly discouraged given the cumulative nephrotoxic risk. Prolonged washout periods of at least 8 weeks are recommended to allow full renal recovery. Kidney function should be assessed before, during, and after any treatment cycle.

Calculate your Adipotide (FTPP) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Adipotide (FTPP) Protocols by Goal

advancedCommunity28 days maximum + 8-week washout
Baseline assessment
Wk 1 (pre-cycle)
None · N/A · N/A
Low-dose phase
Wk 1–2
0.5 mg · Daily · Subcutaneous
Assessment checkpoint
Wk 2 (day 14)
0.5 mg · Daily · Subcutaneous
Continuation (if kidney labs permit)
Wk 3–4
0.5 mg · Daily · Subcutaneous

Expected: Modest fat reduction possible based on primate data extrapolation: but no human efficacy data exists. Many users at this dose may see no measurable change. The primary goal is to avoid kidney damage, not to maximize fat loss.

Monitor: Renal panel at baseline, day 7, day 14, day 28, and at weeks 2, 4, and 6 post-cycle. Urinalysis at each check. GFR at baseline and post-cycle.

How to Inject Adipotide (FTPP)

  1. 1
    Reconstitute one 5 mg vial with 2 mL bacteriostatic water

    Aim the stream against the glass wall, not directly onto the powder. Swirl gently. This gives a concentration of 2.5 mg/mL.

  2. 2
    Step 2

    For a 0.5 mg dose, draw 20 units on an insulin syringe (0.2 mL). For a 1.0 mg dose, draw 40 units (0.4 mL). For a 10 mg vial with 2 mL BAC water, those numbers become 10 units and 20 units respectively.

  3. 3
    Use a 29 to 31 gauge insulin syringe

    Clean the injection site with an alcohol swab and let it dry.

  4. 4
    Inject subcutaneously into the abdomen or thigh

    Rotate sites with each dose. Pinch a fold of skin and insert at a 45-degree angle.

  5. 5
    Administer in the morning

    Stay well hydrated throughout the day (3-plus liters minimum).

  6. 6
    Refrigerate the reconstituted vial at 2 to 8C

    Use within 14 days. Do not freeze reconstituted solution.

  7. 7
    Do not exceed 28 consecutive days

    Follow with an 8-week minimum washout period.

  8. 8
    Step 8

    Monitor kidney function at baseline, day 7, day 14, day 28, and weeks 2, 4, and 6 post-cycle. Stop immediately if creatinine rises more than 20% above your baseline.

Mixing your own vial? Use the Adipotide (FTPP) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Adipotide (FTPP) Stacking Protocols

Works With

Avoid

NSAIDs (ibuprofen, naproxen, aspirin)

Additive nephrotoxic risk: well-documented interaction. NSAIDs reduce renal blood flow, compounding adipotide's renal tubular damage.

Do not combine
Aminoglycoside antibiotics (gentamicin, tobramycin)

Amplified kidney toxicity. Aminoglycosides are independently nephrotoxic via tubular mechanisms.

Do not combine
ACE inhibitors / ARBs

May compound renal hemodynamic effects and worsen kidney function during adipotide use.

Metformin

Increased risk of lactic acidosis if renal function is compromised by adipotide.

Iodinated contrast agents

Compounded nephrotoxicity. Separate by at least 2 weeks from any adipotide use.

Do not combine
Cyclosporine / Tacrolimus

Combined nephrotoxic burden is unacceptable. Both are independently nephrotoxic via different mechanisms.

Do not combine

Estimated Cost

Compounded
$64–90 per 5 mg vial (research-grade). 10 mg vials are also available. Typical 28-day cycle at 0.5 mg/day needs 14 mg total = ~$90–140 depending on product and vial size.

Pricing updated 2026-04-09

Adipotide (FTPP) Side Effects

Kidney damage is the defining risk of adipotide, and it cannot be separated from the drug's mechanism of action. Every primate treated in the 2011 Barnhart study [1] showed dose-dependent renal lesions. The proapoptotic domain D(KLAKLAK)2 causes collateral apoptosis in renal proximal tubular epithelial cells during kidney filtration. This is not an idiosyncratic reaction; it is a predictable pharmacological effect.

The human data made the situation worse. MD Anderson's Phase 1 trial enrolled cancer patients with obesity at 0.03 mg/kg/day, roughly 70 times below the effective primate dose. The trial was still terminated for nephrotoxicity. Human kidneys appear far more sensitive to this mechanism than primate kidneys. No human efficacy data exists because the dose could never reach the therapeutic range.

Renal injury shows up as raised serum creatinine, rising BUN, proteinuria, and hematuria. In primates, these changes were characterized as reversible during washout. Whether that holds for humans is unknown because the trial was stopped too early to study recovery. A creatinine rise of more than 20 to 25% from your baseline should trigger immediate discontinuation.

Bostin Loyd, a bodybuilder widely discussed in forum threads, died while reportedly using approximately 5 mg/day. That's well above any dose tested in clinical research. At that level, off-target apoptosis in renal tubular cells during clearance overwhelms kidney function.

Beyond nephrotoxicity, reported side effects include transient dehydration (the kidneys work harder to clear the compound), mild proteinuria at subclinical levels, and injection site reactions. These are minor next to the renal risk, but proteinuria specifically should trigger immediate discontinuation.

Contraindicated in anyone with pre-existing kidney disease, impaired renal function, or concurrent use of other nephrotoxic agents including NSAIDs, aminoglycosides, iodinated contrast dyes, cyclosporine, or tacrolimus. Pregnancy and breastfeeding are absolute contraindications. No pediatric safety data exists.

If you experience dark or foamy urine, flank pain, back pain, or edema during use, stop immediately. Get labs within 24 hours. Hydration matters enormously; dehydration concentrates the compound in the kidneys during excretion and increases toxicity.

Common Issues & Solutions

Kidney labs look off at day 7: Stop immediately. Don't "wait and see." Renal damage from adipotide can progress quickly and may not be reversible in humans. Hydrate aggressively and recheck in 48 hours.

Dark or foamy urine: Could be proteinuria or hematuria: both are early signs of renal tubular injury. Stop the cycle and get a urinalysis within 24 hours.

No noticeable fat loss after 14 days at 0.5 mg: This is expected for many people. The effective primate dose is 60x higher. Do NOT increase your dose to chase results: you'll hit kidney toxicity before you hit efficacy.

Flank pain or lower back ache: Could indicate kidney inflammation. Stop immediately and get imaging + labs. Don't dismiss this as a muscular issue.

Dehydration symptoms (dark urine, dizziness, dry mouth): The compound concentrates in kidneys during excretion. Dehydration dramatically increases toxicity. Rehydrate immediately and consider stopping the cycle.

Ask AI about this page

Ask AI for a second opinion on Adipotide (FTPP) dosing and side effects

Contraindications

  • Any pre-existing kidney disease or impaired renal function
  • History of nephrotoxic drug reactions
  • Concurrent use of other nephrotoxic agents (NSAIDs, aminoglycosides, contrast dyes)
  • Pregnancy or breastfeeding
  • Dehydration or conditions predisposing to renal hypoperfusion
  • Known hypersensitivity to any component of the peptide
  • Hepatic impairment that may alter peptide clearance
  • Cardiovascular disease or conditions affecting vascular integrity
  • Children or adolescents (no pediatric safety data exists)

Drug Interactions

  • NSAIDs (ibuprofen, naproxen): additive nephrotoxic risk; avoid concurrent use
  • Aminoglycoside antibiotics (gentamicin, tobramycin): amplified kidney toxicity
  • ACE inhibitors and ARBs: may compound renal hemodynamic effects
  • Metformin: increased risk of lactic acidosis if renal function is compromised by adipotide
  • Iodinated contrast agents: compounded nephrotoxicity risk; separate by at least 2 weeks
  • Diuretics: may worsen dehydration and increase renal concentration of the peptide
  • Cyclosporine and tacrolimus: combined nephrotoxic burden is unacceptable
  • NSAIDs (ibuprofen, naproxen, aspirin)

Product Quality

Recommended Monitoring

TestWhenTarget
Serum creatinineBaseline, day 7, day 14, day 28, then weeks 2, 4, 6 post-cycleMust stay within 20% of YOUR baseline. A rise above 25% = stop immediately.
BUN (Blood Urea Nitrogen)Same schedule as creatinine7–20 mg/dL (normal). Trending upward from baseline is a red flag.
Urinalysis with albumin/creatinine ratioBaseline, day 7, day 14, day 28Albumin/creatinine ratio <30 mg/g. Any proteinuria or hematuria = stop.
Estimated GFR (eGFR)Baseline and 4–6 weeks post-cycle>90 mL/min/1.73m² (normal). Any decline warrants extended monitoring.
Serum creatinine

Primary marker for renal tubular damage: the dose-limiting toxicity of adipotide

BUN (Blood Urea Nitrogen)

Reflects kidney filtration function. Rising BUN with stable creatinine can indicate early tubular dysfunction.

Urinalysis with albumin/creatinine ratio

Detects proteinuria and hematuria: both are early markers of renal injury. More sensitive than serum creatinine for catching tubular damage early.

Estimated GFR (eGFR)

Overall kidney function assessment. Comparing pre- and post-cycle GFR tells you whether lasting damage occurred.

Adipotide (FTPP) Before and After

Days 1-7

Initial treatment phase. Based on primate data, measurable changes in body composition may begin. Renal markers (creatinine, BUN) should be monitored closely from the outset. Early signs of kidney stress may appear even at low doses.

Days 8-14

Fat reduction becomes detectable via imaging in animal models. Primate studies showed progressive weight loss during this window. Renal tubular changes may begin to appear on urinalysis. Continued monitoring is essential.

Days 15-21

Significant fat loss is observed in animal models. In obese monkeys, this period corresponded to the steepest weight loss trajectory. Kidney injury markers may become elevated; dose reduction or discontinuation should be considered if creatinine rises above baseline.

Days 22-28

End of the standard 28-day treatment cycle. Primate data showed 7-15% total body weight loss and up to 38% reduction in body fat by this point. Treatment should be discontinued at day 28. Renal function monitoring should continue for at least 4-6 weeks after cessation.

Post-treatment
Weeks 5-12

Washout and recovery phase. Some weight regain is expected as adipose vasculature regenerates over time. Renal lesions observed in primate studies were reported as reversible during washout. Do not restart treatment until all renal markers have normalized.

What to Expect

Days 1 through 7, first week, establishing tolerance: Based on primate data, vascular changes in adipose tissue may begin at the cellular level. Don't expect anything visible. Renal tubular stress can start even at low doses. Most community users report nothing noticeable this week. Some mention mild injection site irritation and a slight uptick in urination. The real purpose of week one is your day 7 kidney labs.

Days 8 through 14, second week, the monitoring window: Fat reduction became detectable via imaging during this period in primates. Your kidney markers may start shifting, and this is the checkpoint that matters most. Users who report any effect typically notice subtle changes in how fat tissue feels (softer, less firm) around days 10 to 14. Scale weight barely moves. Watch for creatinine elevation and mild proteinuria.

Days 15 through 28, second half, risk accumulation: Primate studies showed the steepest weight loss curve here, with 7 to 15% total body weight gone by day 28. Kidney lesions also progressed. Both the wanted effects and the unwanted ones are cumulative. Community users who complete 28 days at low doses report modest abdominal fat reduction, far less dramatic than primate data because the dose is far lower. Watch for proteinuria, creatinine drift, fatigue, and edema.

Weeks 5 through 12, post-cycle washout: Primate kidney lesions were reported as reversible during this phase. Adipose vasculature regenerates over time, so some fat regain is expected. Community users report weight returning over 4 to 8 weeks. Kidney markers typically normalize within 2 to 4 weeks if they were mildly raised. Full renal recovery is not guaranteed in humans. Do not restart until every renal marker has returned to your baseline.

Detailed Timeline: Science vs Community

Days 1–7
Science

Based on primate data, measurable vascular changes in adipose tissue may begin. No visible body composition changes yet. Renal tubular stress may begin even at low doses.

Community

Most users report nothing noticeable in week 1. Some report mild injection site irritation. A few report slight increase in urination.

Days 8–14
Science

In primates, fat reduction became detectable via imaging during this window. Renal markers may start shifting: this is the critical monitoring checkpoint.

Community

Users who report any effect typically start noticing subtle changes in how fat "feels" (softer, less firm) around day 10–14. Weight scale changes are minimal.

Days 15–28
Science

Primate studies showed the steepest weight loss trajectory in this window (7–15% total body weight by day 28). Kidney lesions also progressed. The compound's effects, both wanted and unwanted, are cumulative.

Community

The few users who complete 28 days at low doses report modest fat reduction, primarily in abdominal area. Results are far less dramatic than the primate data would suggest, consistent with doses being far below the effective primate dose.

Weeks 5–12 (post-cycle)
Science

Primate kidney lesions were reported as reversible during washout. Adipose vasculature regenerates over time, so some fat regain is expected. The timeline for vascular regeneration in humans is unknown.

Community

Users report some weight/fat regain over 4–8 weeks post-cycle. Kidney markers typically normalize within 2–4 weeks if they were mildly elevated. Full renal recovery is not guaranteed in humans.

Pharmacokinetics

Half-Life
3h
Bioavailability
Subcutaneous: not formally characterized in humans
Tmax
Estimated 1-2 hours (subcutaneous, based on peptide class)
Data Confidence
low

Source: Estimated from peptide pharmacokinetics; no published human PK data available. Short peptide with D-amino acid stabilization may extend half-life modestly.

Pharmacokinetics: Active Dose Over Time

t½ = ~2-4 hours (estimated)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
9
Structure
Cyclic
Sequence
CKGGRAKDC
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: Not assigned (chimeric research peptidomimetic, no CAS entry)

Who Should Consider Adipotide (FTPP)

  • Research subjects in supervised preclinical settings only
  • Not recommended for any unsupervised human use due to nephrotoxicity
  • Animal models of obesity and adipose tissue biology
  • Investigators studying vascular-targeted drug delivery
  • Researchers exploring prohibitin as a therapeutic target

Related Peptides

What Changed for Adipotide (FTPP)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations

References

  1. [1]A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys (Sci Transl Med 2011) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store lyophilized powder at -20°C, protected from light and moisture
After Reconstitution
Use within 14 days when refrigerated at 2-8°C; do not freeze reconstituted solution
Temperature
-20°C lyophilized; 2-8°C reconstituted

Frequently Asked Questions

Bostin Loyd, a well-known bodybuilder, is widely cited on forums as having died while using approximately 5 mg/day; well above any clinical dose. The compound's proapoptotic domain causes off-target apoptosis in renal tubular cells during clearance, and at high doses this is lethal to renal function.

The therapeutic window between effective and kidney-toxic doses was too narrow to engineer around. The rise of GLP-1 agonists then provided a far safer commercial pathway. Nanoparticle reformulation was explored but couldn't reliably solve the kidney clearance problem.

Serum creatinine, BUN, urinalysis (proteinuria, hematuria), and spot urine albumin/creatinine ratio. Check at baseline, day 7, day 14, and day 28. A creatinine rise of >20–25% from baseline should prompt immediate discontinuation. Post-cycle renal monitoring for 4–6 weeks is essential since tubular repair takes time.

No. Adipose tissue vasculature regenerates over time. The primate washout data showed weight regain as fat depots gradually re-vascularized. The drug doesn't permanently destroy adipocytes; it starves them by destroying their blood supply. Some rebound is expected without concurrent lifestyle changes.

The Phase 1 trial at MD Anderson enrolled cancer patients with obesity at 0.03 mg/kg/day; roughly 70-fold lower than the primate effective dose, and was still terminated due to nephrotoxicity. Human kidneys appear significantly more sensitive than primate kidneys to this mechanism.